Galecto, Inc.
GLTONASDAQ
Healthcare
Biotechnology
$25.23
+0.15(0.6%)
52W $2.22 – $34.14
Galecto, Inc.
$40MMkt Cap
—Rev TTM
-$210MNI TTM
-0.2xP/E TTM
Latest Earnings
10-K
FY FY2025Mar 18, 2026Galecto, Inc. (GLTO), a clinical-stage biopharmaceutical company, reported a substantial net loss of $209.8 million for FY 2025 ended December 31, 2025, widening significantly from $21.4 million in 2024. The primary driver was $174.3 million in acquired in-process research and development expenses from the November 10, 2025, Damora Therapeutics asset acquisition, which bolstered the pipeline with mutCALR-targeting antibodies DMR-001, DMR-002,...
What Changed Recently
Fundamentals
How The Business Makes Money
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Industry Biotechnology
Company Profile
CIK0001800315
ISINUS36322Q2066
CUSIP36322Q107
Phone457 070 5210
Address75 State Street, Boston, MA, 02109, US
SEC EDGAR